Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
FiercePharma14 小时
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
FiercePharma6 天
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
JD Supra6 天
GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from ...
On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...
Yahoo Finance6 天
Outsourcing Facilities Association Sues FDA Over Sudden Removal of Tirzepatide from Drug ...
OFA is also seeking a temporary order that would enjoin FDA from taking action against OFA’s members for making compounded versions of Tirzepatide during the pendency of the lawsuit. In the ...
CNN5 天
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
The drug uses the active ingredient tirzepatide and was approved by the FDA in May 2022 for type 2 diabetes; although McCaskill said her blood sugar was elevated, she didn’t have diabetes ...